Protecting the world against pertussis and other global re-emerging diseases
BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced many proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across all continents.
State-of-the-art manufacturing capabilities
BioNet commits to develop and manufacture innovative high-quality vaccines that comply with applicable regulatory requirements. BioNet aims to integrate quality beyond compliance in both products and processes through continuous improvement of our quality system.
Our vaccines are manufactured in accordance to Good Manufacturing Practices (GMP) PIC/S standards, and tested at each manufacturing step as per pharmacopeia requirements in our own quality control and testing facilities.
BioNet Key Facts
3
licensed
recombinant pertussis vaccines
200+
collaborators
sharing their passion for vaccines
30+
years’ experience
in international management
20+
clinical trials experience
10+
mRNA
candidates
LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition
Andernach – LTS, a leading pharmaceutical technology company, and BioNet, a biotech manufacturer specializing in genetically engineered vaccines, announced today their selection as a Concept Stage winner of the #PatchForwardPrize, a $50 million challenge by BARDA to advance microneedle patch-based RNA vaccine technologies. This recognition highlights the groundbreaking potential of their collaboration in mRNA vaccine development and delivery.
The Patch Forward Prize, part of the Project NextGen initiative led by the Biomedical Advanced Research and Development Authority (BARDA), aims to accelerate next-generation vaccine technologies. By fostering partnerships between vaccine developers and delivery platform innovators, the competition drives progress from concept to clinical stages, paving the way for transformative advancements in global health.
BARDA announces $8 million in awards to advance microneedle patch-based RNA vaccine development as part of the Patch Forward Prize
Today, the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), announced four winners of the Concept Stage of the Patch Forward Prize. Each winner received $2 million to advance innovative microneedle patch-based technologies for RNA-based COVID-19, seasonal influenza, and pandemic influenza vaccines that enable easier and faster vaccine distribution and administration, improving rapid response capabilities and the nation’s health security.
